SOL Strategies Inc.: SOL Strategies's Houdini Swap to Bring Private Cross-Chain Transactions to Jumper

SOL Strategies Inc. (CSE: HODL; NASDAQ: STKE) said it is integrating its non-custodial, privacy-focused Houdini Swap with Jumper, which handles over $1B in monthly volume. The company later corrected a June 18 release stating the integration was live; it is still in progress. Once live, Jumper users can run private swap/bridge/receive transactions on jumper.xyz via Houdini’s API with AML/KYT screening.

Original reporting
Published Jun 18, 2026, 5:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 5:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SOL Strategies Inc.: SOL Strategies's Houdini Swap to Bring Private Cross-Chain Transactions to Jumper — source image
Decision brief

The 30-second read

$STKEBullishLow
01

Why it matters

The integration is positioned to embed Houdini’s private-swap rail into Jumper’s LI.FI-based routing so users can execute swap/bridge/receive privately on jumper.xyz once the integration goes live. The release also corrects an earlier statement that the integration was already live at issuance.

02

Market read

A product integration update for crypto privacy infrastructure; potential incremental adoption catalyst but no confirmed go-live timing or financial impact disclosed.

03

What to watch

Traders may want to watch for actual on-platform availability, user adoption metrics, and whether compliance/privacy features face integration friction or policy scrutiny.

Relevance 4/10Novelty 4/10Timing: today’s corrected PR: integration not yet live; private transactions expected after go-live

Background

SOL Strategies’ Houdini Swap is a non-custodial, privacy-focused cross-chain swap aggregator; Jumper is a multi-chain app with $1B+ monthly volume.

Company-level read

Ticker impact

$STKEBullishMedium confidence
Context

SOL Strategies says Houdini’s API integration with Jumper is in progress and will enable private swap/bridge/receive on jumper.xyz once live.

Expected impact

Near-term impact likely limited; any move would depend on broader crypto risk sentiment and follow-through on “go-live” timing.

Evidence & confidence

The article is a product/integration update with no financial metrics or confirmed launch date; it does, however, correct an earlier “live” claim, which may temper immediate enthusiasm.

Market effects

Highlights ongoing demand for privacy-preserving cross-chain routing and compliance tooling (AML/KYT) in DeFi aggregators.

No clear regional macro linkage; primarily crypto/tech sentiment-driven.

Relevant to cross-chain liquidity and privacy tooling narratives across major multi-chain apps.

Counterpoint

The correction (“not yet live”) suggests execution risk; without a specific launch date or measurable KPIs, the market may discount the impact.

Key entities

  • SOL Strategies Inc.

    Operator of Houdini Swap; announced the Houdini–Jumper integration status and expected private transaction availability.

  • Houdini Swap

    Wholly-owned, non-custodial, privacy-focused cross-chain swap aggregator/API.

  • Jumper

    Multi-chain aggregation app processing $1B+ monthly volume; will host private transactions via embedded Houdini API.

  • LI.FI

    Developer behind Jumper’s routing infrastructure; provides bridge/DEX routing across many chains.

Related articles

$STKEMed

SOL Strategies Inc. (STKE): Financial results for Q4 2026

SOL Strategies Inc. (STKE) furnished an SEC Form 6-K — earnings release. SOL STRATEGIES ANNOUNCES PRELIMINARY UNAUDITED FISCAL FOURTH QUARTER RESULTS INCLUDING REVENUE OF APPROX. $4.0 MILLION CAD Houdini Swap Generates $3.4 Million CAD in Revenue on Volume of $326 Million CAD During First Full Quarter of Operations under SOL Strategies TORONTO, Novemb

$ELOXMed

Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation

Eloxx Pharmaceuticals (ELOX) published Phase 2a trial results in the Journal of Clinical Investigation, showing exaluren increased collagen IV production and improved kidney cell structure in patients with nonsense mutation Alport syndrome. The drug was well-tolerated. The company is conducting a Phase 2b study (EXACT) with topline data expected in mid-2027.

$METAMed

Meta staff flagged Muse AI reading Signal messages and mixing user data

Meta's Muse AI agent was flagged by employees for reading encrypted Signal messages and mixing user data, according to a Reuters investigation. Staff reported privacy violations, including access to bank account balances and unauthorized actions. Meta attributed issues to 'model hallucinations' and stated many problems have been fixed. Signal's president criticized Meta's privacy practices. Meta defended its testing processes, noting differences between employee and public versions.